Skip to main content
SpringerLink
Log in

Immunopotentiation and Delivery Systems for Antigens for Single-Step Immunization: Recent Trends and Progress

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The use of adjuvants for immunopotentiation has been investigated since the 1920s and a number of comprehensive reviews and monographs have been published on this subject. A recent trend in immunopotentiation has been the use of delivery systems which allow for sustained or controlled release of antigens and which induce prolonged immunity following a single dose. This concept has been termed either single-step or single-shot immunization. The delivery system has been modulated to potentiate the immune response either by delivering the antigen (and perhaps an adjuvant or adjuvants) either over a prolonged period of time or in a predetermined sequence or by incorporating substances with immunoadjuvant properties (e.g., lecithin and certain biodegradable polymers) as carriers within the delivery system. This Review focuses on the progress made in the design of delivery systems for immunopotentiation. Particular emphasis is given to delivery systems designed to achieve single-step immunization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. D. J. Stewart, B. L. Clark, J. E. Peterson, D. A. Griffiths, E. F. Smith, and I. J. O'donnell. Effect of pilus dose and type of Freund's adjuvant on the antibody and protective responses of vaccinated sheep to Bacteroides nodosus. Res. Vet. Sci. 35:130–137 (1983).

    Google Scholar 

  2. S. Lukes. Dependency of resistance of mice immunised against Taenia crassiceps on the dose of soluble antigen. Folia Parasitol. 34:329–333 (1987).

    Google Scholar 

  3. T. W. F. Pay and P. J. Hingley. Correlation of 140S antigen dose with the serum neutralising antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine 5:60–64 (1987).

    Google Scholar 

  4. J.-G. Hu, A. Ide, T. Yokoyama, and T. Kitagawa. Studies on the optimal immunisation schedule of the mouse as an experimental animal. The effect of antigen dose and adjuvant type. Chem. Pharm. Bull. 37:3042–3046 (1989).

    Google Scholar 

  5. J.-G. Hu, T. Yokoyama, and T. Kitagawa. Studies on the optimal immunization schedule of experimental animals. V. The effects of the route of injection, the content of Mycobacteria in Freund's adjuvant and the emulsifying antigen. Chem. Pharm. Bull. 38:1961–1965 (1990).

    Google Scholar 

  6. D. L. Wise, D. J. Trantolo, R. T. Marino, and J. P. Kitchell. Opportunities and challenges in the design of implantable biodegradable polymeric systems for the delivery of antimicrobial agents and vaccines. Adv. Drug Deliv. Rev. 1:19–39 (1987).

    Google Scholar 

  7. I. Nakashima, F. Ohta, T. Kobayashi, O. Kato, and N. Kato. Effect of antigen doses and time intervals between antigen injections on secondary, tertiary and quaternary antibody responses. Immunology 26:443–454 (1974).

    Google Scholar 

  8. M. Murray, P. B. Robinson, C. Grierson, and R. A. Crawford. Immunisation against Nippostrongylus brasiliensis in the rat. Acta Trop. 36:297–322 (1979).

    Google Scholar 

  9. R. C. H. Lau. Detection of diphtheria toxin antibodies in human sera in New Zealand by ELISA. J. Hyg Cambr. 96:415–418 (1986).

    Google Scholar 

  10. J. A. Reynolds, D. G. Harrington, C. L. Crabbs, C. J. Peters, and N. R. Di Luzio. Adjuvant activity of a novel metabolizable lipid emulsion with inactivated viral vaccines. Infect. Immun. 28:937–943 (1980).

    Google Scholar 

  11. M. Brugh, H. D. Stone, and H. W. Lupton. Comparison of inactivated Newcastle disease viral vaccines containing different emulsion adjuvants. Am. J. Vet. Res. 44:72–75 (1983).

    Google Scholar 

  12. H. S. Warren, F. R. Vogel, and L. A. Chedid, Current status of immunological adjuvants. Annu. Rev. Immunol. 4:369–388 (1986).

    Google Scholar 

  13. B. A. Vanselow. The application of adjuvants to veterinary medicine. Vet. Bull. 57:881–896 (1987).

    Google Scholar 

  14. R. Edelman. Vaccine adjuvants. Rev. Infect. Dis. 2:370–383 (1980).

    Google Scholar 

  15. S. Wright and L. Huang. Antibody-directed liposomes as drug delivery vehicles. Adv. Drug Deliv. Rev. 3:343–389 (1989).

    Google Scholar 

  16. N. van Rooijen. Liposomes as carrier and immunoadjuvant of vaccine antigens. Adv. Biotechnol. Process. 13:255–279 (1990).

    Google Scholar 

  17. C. R. Alving. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 140:1–13 (1991).

    Google Scholar 

  18. C. Langhein and J. F. E. Newman. Antibody response to bacterial antigens covalently bound to biodegradable polymerized serum albumin beads. J. Appl. Bacteriol. 63:443–448 (1987).

    Google Scholar 

  19. P. M. Callahan, A. L. Shorter, and S. L. Hem. The importance of surface charge in the optimisation of antigen-adjuvant interactions. Pharm. Res. 8:851–858 (1991).

    Google Scholar 

  20. G. Ramon. Procédés pour accroitre la production des antitoxines. Ann. Inst. Pasteur 40:1–10 (1926).

    Google Scholar 

  21. J. H. Eldridge, J. K. Staas, J. A. Meulbroek, T. R. Tice, and R. M. Gilley. Biodegradable and biocompatible poly (D,L-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxinneutralizing antibodies. Infect. Immun. 59:2978–2986 (1991).

    Google Scholar 

  22. A. K. Lascelles, G. Eagleson, K. J. Beh, and D. L. Watson. Significance of Freund's adjuvant/antigen injection granuloma in the maintenance of serum antibody response. Vet. Immunol. Immunopathol. 22:15–27 (1989).

    Google Scholar 

  23. R. Hunter, M. Oslen, and S. Buynitzky. Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formation on titre and isotype of antibody. Vaccine 9:250–255 (1991).

    Google Scholar 

  24. A. C. Allison and G. Gregoriadis. Liposomes as immunological adjuvants. Nature 252:252 (1974).

    Google Scholar 

  25. W. Wagner, K. Beckman, M. G. Edinger, S. Deodhar, and J. R. Battisto. Immunotherapy with allergen sequestered in liposomes. J. Allergy Clin. Immunol. 73:118 (abstr. 39) (1984).

    Google Scholar 

  26. N. Arora and S. V. Gangal. Allergen entrapped in liposomes reduce allergenicity and induce immunogenicity on repeated injections in mice. Int. Arch. Allergy Appl. Immunol. 91:22–29 (1990).

    Google Scholar 

  27. R. J. Genco, R. Linzer, and R. T. Evans. Effect of adjuvants on orally administered antigens. Ann. N.Y. Acad. Sci. 409:650–668 (1983).

    Google Scholar 

  28. N. Latif and B. K. Bachhawat. Liposomes in immunology. J. Biosci. 6:491–502 (1984).

    Google Scholar 

  29. C. R. Alving. Liposomes as carriers for vaccines. In M. J. Ostro (ed.), Liposomes; From Biophysics to Therapeutics, Marcel Dekker, New York, 1987, pp. 195–218.

    Google Scholar 

  30. G. Gregoriadis. Immunological adjuvants: A role for liposomes. Immunol. Today 11:89–97 (1990).

    Google Scholar 

  31. N. van Rooijen, R. van Nieuwmegen, N. Kors, and P. Eikelenboom. The development of specific antibody-containing cells in the spleen of rabbits during the secondary immune response against free or liposome-associated albumin antigen. Anat. Rec. 208:579–587 (1984).

    Google Scholar 

  32. D. T. O'Hagan, D. Rahman, J. P. McGee, H. Jeffery, M. C. Davies, P. Williams, S. S. Davies, and S. J. Challacombe. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73:239–242 (1991).

    Google Scholar 

  33. M. Singh, A. Singh, and G. P. Talwar. Controlled delivery of diphtheria toxoid using biodegradable poly (D,L-lactide) microcapsules. Pharm. Res. 8:958–961 (1991).

    Google Scholar 

  34. P. Artursson, P. Edman, and I. Sjöholm. Biodegradable microspheres. II. Immune response to a heterogeneous and an autologous protein entrapped in polyacryl starch microparticles. J. Pharmacol. Exp. Ther. 234:255–260 (1985).

    Google Scholar 

  35. J. B. Dewar, D. A. Hendry, and J. F. E. Newmann. Biodegradable serum albumin polymers for the sustained release of virus antigens in vaccines. S. Afr. Med. J. 65:564–565 (1984).

    Google Scholar 

  36. R. Langer and J. Folkman. Polymers for the sustained release of proteins and other macromolecules. Nature 263:797–800 (1976).

    Google Scholar 

  37. I. Preis and R. S. Langer. A single step immunization by sustained antigen release. J. Immunol. Methods 28:193–197 (1979).

    Google Scholar 

  38. R. Langer. Polymers for the sustained release of macromolecules: Their use in a single-step method of immunization. Methods Enzymol. 73:57–75 (1981).

    Google Scholar 

  39. J. Kohn, S. M. Niemi, E. C. Albert, J. C. Murphy, R. Langer, and J. G. Fox. Single-step immunisation using a controlled release, biodegradable polymer with sustained adjuvant activity. J. Immunol. Methods 95:31–38 (1986).

    Google Scholar 

  40. J. B. Kohn, R. S. Langer, S. M. Niemi, and J. G. Fox. Biodegradable polymeric drug delivery system with adjuvant activity. International Patent Publication No. WO 88/02262 (1988).

  41. R. L. Beck. Mammal immunisation. U.S. Patent No. 4 919 929 (1990).

  42. J. P. Opdebeeck and I. G. Tucker. A cholesterol implant used as a delivery system to immunize mice with bovine serum albumin. J. Control. Release 23:271–279 (1993).

    Google Scholar 

  43. M. Z. I. Khan, I. G. Tucker, and J. P. Opdebeeck. Cholesterol and lecithin implants for sustained release of antigen: Release in vitro and antibody response in mice. Int. J. Pharm. 76:161–170 (1991).

    Google Scholar 

  44. M. Z. I. Khan, I. G. Tucker, and J. P. Opdebeeck. Evaluation of cholesterol-lecithin implants for sustained delivery of antigen: Release in vivo and single-step immunisation of mice. Int. J. Pharm. 90:255–262 (1993).

    Google Scholar 

  45. P. Y. Wang. Prolonged release of insulin by cholesterol-matrix implant. Diabetes 36:1068–1072 (1987).

    Google Scholar 

  46. P. Y. Wang. Implant preparations for delivery of bioactive materials. European Patent No. 0246 540 (1987).

  47. L. F. Fries, D. M. Gordon, R. L. Richards, J. E. Egan, M. R. Hollingdale, M. Gross, C. Silverman, and C. R. Alving. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA 89:358–362 (1992).

    Google Scholar 

  48. R. L. Richards, G. M. Swartz, Jr., C. Schultz, M. D. Hayre, G. S. Ward, W. R. Ballou, J. D. Chulay, W. T. Hockmeyer, S. L. Berman, and C. R. Alving. Immunogenicity of liposomal malaria sporozite antigen in monkeys: Adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine 7:506–512 (1989).

    Google Scholar 

  49. S. Cohen, H. Bernstein, C. Hewes, M. Chow, and R. Langer. The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. Proc. Natl. Acad. Sci. USA 88:10440–10444 (1991).

    Google Scholar 

  50. T. M. S. Chang. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J. Bioeng. 1:25–32 (1976).

    Google Scholar 

  51. J. H. Eldridge, J. K. Staas, J. A. Meulbroek, J. R. McGhee, T. R. Tice, and R. M. Gilley. Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28:287–294 (1991).

    Google Scholar 

  52. L. J. Silvestri and R. H. Pyle. Sustained release dosage forms. International Patent Publication No. WO 90/09166 (1990).

  53. J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. A. Staas, R. M. Gilley, and T. R. Tice. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release 11:205–214 (1990).

    Google Scholar 

  54. N. A. Mitchison. Dose, frequency and route of administration of antigen. In F. Borek (ed.), Immunogenicity, North-Holland, Amsterdam, 1972, pp. 87–111.

    Google Scholar 

  55. D. W. Dresser. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 5:378–388 (1962).

    Google Scholar 

  56. G. J. V. Nossal. Immunogenicity and immunopotentiation. In G. C. Woodrow and M. M. Levine (eds.), New Generation Vaccines, Marcel Dekker, New York, 1990, pp. 85–94.

    Google Scholar 

  57. E. Sercarz and A. H. Coons. Specific inhibition of antibody formation during immunological paralysis and unresponsiveness. Nature 184:1080–1082 (1959).

    Google Scholar 

  58. L. C. Sauerbronn Maia, N. M. Vaz, and E. M. Vaz. Effect of soluble antigen on IgE responses in the mouse. Int. Arch. Allergy 46:339–344 (1974).

    Google Scholar 

  59. A. K. Walduck and J. P. Opdebeeck. The effect of antigen delivery profile on the level, avidity and isotype of murine antibodies (submitted for publication) (1993).

  60. A. A. Amkraut, S. I. Yum, and M. B. Rittenberg. Specific suppression of IgG plaque forming cells (PFC) by continuous administration of antigen from an implantable delivery system. Fed. Proc. 35:675 (abstr. 2584) (1976).

    Google Scholar 

  61. M. N. Abo-Shehada and I. V. Herbert. Investigation of effects of some immunoadjuvants and routes of antigen administration in raising antibodies in rabbits against metacestode cyst antigens of Taenia multiceps. J. Immunol. Methods 61:345–350 (1983).

    Google Scholar 

  62. P. N. Shek, B. Y. K. Yung, and N. Z. Stanacev. Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation. Immunology 49:37–44 (1983).

    Google Scholar 

  63. P. N. Shek, B. Y. K. Yung, and N. Z. Stanacev. Physicochemical and immunological properties of albumin-associated dialkylether phosphatidylcholine liposomes. Biochim. Biophys. Acta 855:3–40 (1986).

    Google Scholar 

  64. D. Davis and G. Gregoriadis. Liposomes as adjuvants with immunopurified tetanus toxoid: Influence of liposomal characteristics. Immunology 61:229–234 (1987).

    Google Scholar 

  65. T. D. Heath, D. C. Edwards, and B. E. Ryman. The adjuvant properties of liposomes. Biochem. Soc. Trans. 4:129–133 (1976).

    Google Scholar 

  66. N. van Rooijen, and R. van Nieuwmegen. Liposomes in immunology: Multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol. Commun. 9:243–256 (1980).

    Google Scholar 

  67. S. L. Snyder and W. E. Vannier. Immunologic response to protein immobilized on the surface of liposomes via covalent azobonding. Biochim. Biophys. Acta 772:288–294 (1984).

    Google Scholar 

  68. P. N. Shek and B. H. Sabiston. Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation. Immunology 47:627–632 (1982).

    Google Scholar 

  69. P. Artursson, I.-L. Martensson, and I. Sjöholm. Biodegradable microspheres. III. Some immunological properties of polyacryl starch microparticles. J. Pharm. Sci. 75:697–701 (1986).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, The University of Queensland, Brisbane, Queensland, 4072, Australia

    M. Zahirul I. Khan

  2. Department of Parasitology, The University of Queensland, Brisbane, Queensland, 4072, Australia

    Joan P. Opdebeeck

  3. School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand

    Ian G. Tucker

Authors
  1. M. Zahirul I. Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan P. Opdebeeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian G. Tucker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khan, M.Z.I., Opdebeeck, J.P. & Tucker, I.G. Immunopotentiation and Delivery Systems for Antigens for Single-Step Immunization: Recent Trends and Progress. Pharm Res 11, 2–11 (1994). https://doi.org/10.1023/A:1018977107167

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018977107167

Search

Navigation